August is typically a calmer month, but we’re seeing continued positive momentum. The number of billable Dosell units increased by 6% compared to July, giving us a stable foundation heading into the fall. The largest growth came from the Netherlands with an 8% increase, but other markets are also showing strength. This is yet another clear sign that our solution is not only in demand – but increasingly used.

Continued Strong Interest in Sweden
Interest from Swedish municipalities remains high. In August, we conducted 17 digital demos – with recurring comments such as:

“It’s truly so user-friendly!”
“This fits many more areas in the municipality than what we’re currently working with.”

We’ve been actively preparing for the launch of three new municipalities going live in September. At the same time, we’re seeing that many municipalities are now awaiting the national ADDA procurement – Sweden’s first coordinated framework for medical dispensers, with an estimated value of 80 MSEK annually. We strongly believe this will act as a catalyst for the market and help accelerate the adoption of medical dispensers throughout Sweden.

Finland: Pilot Launch in September
Our new partner in Finland, AddSecure Smart Care Oy, has made significant progress during August. A pilot is set to begin in mid-September. This is an important milestone for Dosell as a company and marks a strong start to our establishment in Finland.

The Netherlands: Rising Demand and Rapid Deliveries
The holiday season is over – and the need for scalable medication management solutions in the Netherlands has become even more evident. In August, several care organizations decided to bring forward their planned Dosell deployments in direct response to increasing staff shortages in elderly care.

Thanks to strong local presence, experience from earlier rollouts, and access to stocked devices, our partner was able to meet the demand swiftly.

New Software and a Smarter Loading Process
Over the summer, we completed and began rolling out a new software version of Dosell. It includes improvements in stability, performance, and user experience – especially valuable in large-scale implementations.

We’ve also developed a simplified loading process. This enhances our ability to integrate into existing infrastructures and strengthens our readiness to scale in new markets.

Prepared for September – and the Rest of the Year
There’s a lot ahead:

  • Three municipalities go live in September
  • More demos and procurement processes
  • Dosell’s first Partner Day
  • Meetings with potential new partners
  • Trainings for upcoming launches

We look forward to reporting a strong September in the next monthly update – and thank you for your continued trust!

iZafe Group AB (publ.) presents today, August 29th, its report for the second quarter.

Financial Performance in Summary

  • Total net revenue for the quarter amounted to 1,136 TSEK (168), now primarily consisting of recurring license revenues, with only a small share attributable to hardware sales. This is in clear contrast to the same period last year, when license revenues were marginal. The development reflects that our business model is now firmly established, providing a stable foundation of recurring revenues.
  • Operating result (EBIT) for the quarter amounted to -4,277 TSEK (-4,011).
  • Operating result before depreciation and amortization (EBITDA) for the quarter amounted to -3,295 TSEK (-3,027). The outcome is primarily explained by strategic inventory adjustments, where older components no longer relevant for production have been phased out, as well as continued investments in development. These initiatives are part of our long-term strategy aimed at strengthening the product portfolio and securing the company’s future growth and success.
  • Result after financial items for the quarter amounted to -4,503 TSEK (-4,037).
  • Cash flow from operating activities for the quarter amounted to -1,715 TSEK (-4,155).
  • Earnings per share for the quarter before/after dilution amounted to -0.01 SEK (-0.02).
  • Equity per share at the end of the period amounted to 0.03 SEK (0.07).
  • The equity ratio at the end of the period was 50.1% (73.3%).

Significant events during the quarter

  • iZafe Group AB has signed a Letter of Intent (LOI) with Germany-based JDM Innovation GmbH, part of the PHOENIX group, to integrate the Dosell medication robot with the Smila dose dispenser into a joint digital platform for in-home medication management. The collaboration targets municipalities and healthcare providers across Europe, aiming to simplify implementation, improve adherence, and free up time in healthcare.
  • iZafe Group AB has reached a significant milestone with over 1,000 active Dosell units in operation across Europe. This marks a breakthrough for the company’s commitment to safe and digital in-home medication management and demonstrates that the solution is now established and scalable. The milestone was celebrated with an investor event in Stockholm on June 12.
  • iZafe Group AB has carried out a directed share issue of approximately 10 MSEK through the issuance of 43.48 million Class B shares at a subscription price of 0.23 SEK per share. The proceeds will be used to repay a loan to Exelity AB, as well as to strengthen working capital and finance continued growth and strategic investments.

Significant events after the end of the quarter

  • iZafe Group AB has continued to grow during the quarter with an increase in billable Dosell units and strong demand in Sweden, the Netherlands, and Spain. Three new municipalities have initiated operations, the partner TCCN is launching Dosell TV in the Netherlands, and over 50 pharmacies in Spain have joined the Savioo Home concept. The company is experiencing growing commercial momentum and is engaged in discussions with new partners for continued expansion.
  • iZafe Group AB has launched an exclusive shareholder offer in which private individuals holding shares worth at least SEK 50,000 are offered a free Dosell with a subscription. The aim is to reward loyalty and give more people the opportunity to experience the benefits of the company’s solution for safe and adherent medication management.

Forecast
In this report, we present a forecast graph illustrating our expected growth in both ARR and active Dosell units over the coming years. The forecast is based on our current markets and key performance indicators, outlining a clear path toward an exponential increase in recurring revenue as more units become activated. By the end of 2024, our ARR reached approximately 1.7 MSEK, reflecting a 326% increase compared to the previous year.

In 2025, this growth is expected to accelerate further, with ARR projected to reach 10 MSEK by year-end, a 352% increase. Beyond that, ARR is expected to continue growing rapidly, more than eightfold by 2029, when we anticipate exceeding 85 MSEK. We will track this forecast on a quarterly basis to provide our shareholders with a clear view of our actual progress and how we are advancing toward our financial goals.

2023 2024 2025 2026 2027 2028 2029
ARR (MSEK) 0.3 1.7 10 22.5 42.3 63.9 85.5
Growth of Dosells 0% 326% 352% 125% 69% 41% 29%

Comments from the CEO
iZafe Group is in the midst of a decisive transition – from product development and market cultivation to tangible growth and operational impact. The second quarter clearly demonstrates that our business model works: we are growing, we are scaling, and we have now established a recurring revenue base that provides both stability and predictability. At the same time, we are entering a phase with even greater potential, where our market position can be significantly strengthened.

Over 30% ARR growth since Q1 – more than 250% compared to last year
Our recurring revenue base (ARR) has grown by more than 30% since Q1 and is now over two and a half times higher than the same period last year. This confirms that our solution is not only gaining ground – it is actively used and perceived as value-creating. We see the results in the form of more customers, across more regions, and an increasing number of units per customer.

The Netherlands – stress test, stability and continued expansion
In the Netherlands, the number of active units increased by more than 45% during the quarter. Our partner TCCN demonstrates with great commitment how Dosell can scale rapidly when organization and demand work hand in hand. In July, we faced an unexpected stress test when our network provider experienced two major outages. Thanks to swift communication, effective crisis management, and close collaboration with our partners, the impact was minimized.

The incident served as confirmation of both robustness and collaboration – and reinforces our conviction that we have a solution capable of withstanding even unforeseen challenges. To further reduce future risks, we are now strengthening our technical redundancy. Notably, users connected via WiFi were not affected at all – a clear argument for the value of offering multiple connectivity options.

Sweden – stable base and strong pipeline for the autumn
Despite the usual summer slowdown in the municipal sector, progress in Sweden continued. Following a successful pilot, one municipality chose to terminate its previous supplier and sign a direct agreement with Dosell, including an initial order of 30 units. Three new municipalities are scheduled to launch in August, and 15 digital demonstrations are already booked.

We have thus laid the foundation for stronger geographical coverage and broader market trust – developments expected to drive a significant increase in volume during the second half of the year.

Europe – more markets, deeper partnerships
The second quarter also marked the beginning of the next phase in our European expansion. In Spain, our partner Ti Medi has taken a larger step by beginning direct collaborations with pharmacy chains to scale the use of Dosell. Interest is growing – even though the concept of medication dispensers is still new to the market. However, we see clear signs of emerging understanding and believe we are approaching a “ketchup effect.” Ti Medi works methodically, has a strong network, and is the right partner to drive progress in this important market.

In Finland, we have signed a partnership agreement with AddSecure Smart Care Oy, which has already placed its first order and has an ambitious launch plan for the autumn. This marks an important milestone in our Nordic expansion.

In addition, we signed a Letter of Intent with JDM Innovation (part of the Phoenix Group), with the aim of establishing a strategic partnership for broader European expansion. By combining our technology with their logistics expertise and established network within pharmacies and pharmaceuticals, we see strong potential to scale Dosell further.

At the same time, we continue to evaluate several other markets. Our proven business model, technical platform, and growing partner structure give us a unique position for rapid expansion as soon as the right opportunities arise.

Strengthened capital base and increased shareholder engagement
During the quarter, we completed a directed share issue of approximately 10 MSEK, which strengthens our financial position and enables continued execution of our growth strategy. Our exclusive shareholder offer – giving the opportunity to test Dosell with a free subscription – has been met with strong interest, a clear sign of the growing engagement around our solution. It is also worth noting that a loan maturing on June 30 was repaid at the beginning of July, which impacts the cash position reported in this report.

Autumn 2025 – from proof to expansion
We enter the autumn with strong conditions: a product that works, a business model that scales, and a market showing increased interest. But it is now that the next phase begins – where business dialogues must be converted into concrete launches, and pilots into large-scale implementations.

The target of reaching 10 MSEK in ARR before the end of the year remains firm – and we are on track. At the same time, continued execution, focus, and close collaboration between our team, partners, and users are required to succeed.

I would like to extend a big thank you to everyone who is part of this journey. Together we are building the future of medication management – and we are only just getting started.

Anders Segerström
Chief Executive Officer, iZafe Group

July is traditionally a quieter month, something we accounted for in our planning and budget. But that doesn’t mean we’ve been idle. On the contrary – the month brought both challenges and achievements, showing that we are building an increasingly strong company, with a team and partner network that can deliver even under pressure.

A Stress Test in the Netherlands
In July, our network provider experienced two major service outages, which temporarily impacted our operations – particularly in the Netherlands. It was a testing situation for both us and our partners. However, thanks to fast and clear communication, effective crisis management, and close collaboration, we were able to minimize the impact for our users.

As our partner in the Netherlands put it: it was a tough day, but also a clear proof that we have the right product, the right people, and the right mindset to get through even major challenges. It further strengthens our confidence in the future.

We are now working intensively to build increased redundancy to reduce the risk of future network disruptions. It’s also worth highlighting that users connected via WiFi were not affected at all – demonstrating the value of having multiple connectivity options.

Stable Usage and ARR Growth
As expected, we didn’t see a significant increase in the number of units during July. The vacation period affects many operations, especially in Sweden. But we are pleased to report that:

  • The Netherlands saw a 5.5% increase in the number of units – even during the holiday period.
  • ARR increased during July, thanks to sales of additional services and upgrades.

This confirms that Dosell is not just being installed – it is continuously used and creating value.

Progress in Sweden
Despite the summer slowdown in many municipalities, our momentum remains strong:

  • We won a direct procurement where a municipality, after a successful pilot, is switching from their previous supplier to Dosell and placing an order for 30 units.
  • 3 new municipalities will launch in August – continuing our geographic expansion.
  • Interest remains high – 15 digital demonstrations are already booked for August with Swedish municipalities.

Comments like “I hear nothing but that it works great” are strong indicators of the stability and value Dosell provides.

Spain – Next Step Toward Wider Rollout
In Spain, our partnership with Ti Medi continues to gain attention. In July, La Vanguardia published an article highlighting how Ti Medi is now taking the next step by working directly with pharmacy chains to scale the use of Dosell.

That said, it’s important to recognize that the concept of medication dispensers is still new to the Spanish market, and it will take some time for both users and healthcare providers to fully appreciate its benefits. In countries like the Netherlands and across the Nordics, the solution has gained broader adoption and is already seen as a natural part of future medication management.

We’re confident that Spain will get there too – and once it does, we expect a classic “ketchup effect.” Ti Medi has a strong presence, a clear plan, and is working methodically to build understanding and demand. This makes them the ideal partner to drive development forward in this important market.

Read the article: La Vanguardia – Ti Medi

Finland – New Market with a Strong Partner
In July, we signed an agreement with AddSecure Smart Care Oy, who will now launch Dosell in the Finnish market. They have already placed their first order and have an ambitious plan for the autumn. This is an important piece in our Nordic expansion, and we look forward to a strong collaboration.

Strong Engagement from Our Shareholders
We are very pleased that so many shareholders have taken advantage of our exclusive offer – where shareholders can receive a Dosell device with a free subscription for a limited time. The offer has already generated many registrations, which shows strong interest and engagement. We hope even more shareholders will take the opportunity to try Dosell and experience the value it creates – both for individuals and society.

Read more and register here: https://dosell.se/aktieagarforman/

Charging Up for a Strong Autumn
Our team has had a well-deserved break during the summer – something that was much needed after an intense start to the year. Although many had to step in briefly during their holidays due to our small and committed team, the recovery time has been important.

Now, we are fully recharged and ready for an eventful autumn.

We have a clear plan, strong partners, and a goal that feels more within reach than ever: to reach SEK 10 million in ARR before the end of the year.

Thank you for following our journey – and thank you to all shareholders, customers, and partners who make it possible.

iZafe Group AB (publ.) has signed an agreement with AddSecure Smart Care Oy for the distribution of the medication dispenser Dosell on the Finnish market. The agreement represents a strategically important step in iZafe Group’s international expansion and further strengthens the company’s presence in the Nordic region.

Through this partnership, iZafe Group gains access to a well-established partner with extensive reach in the Finnish welfare technology sector. AddSecure Smart Care Oy brings many years of experience delivering digital safety solutions to municipalities and home healthcare providers – making them an ideal partner for introducing Dosell in Finland.

Finland represents a market with growing demand for safe, efficient, and user-friendly medication management in the home. By combining proven technology with strong local presence, the partnership creates a solid foundation for long-term commercial success.

“This agreement gives us a strong foothold in Finland and opens up significant growth opportunities. We look forward to working with AddSecure to improve medication adherence and safety for even more people,” says Anders Segerström, CEO of iZafe Group.

Strong Start to the Summer – and Continued Focus on Reaching 10 MSEK in ARR

June was marked by strategic initiatives and a clear forward focus. The summer months are traditionally quieter, which is also reflected in our budget, but we remain firmly on track toward our stated goal of reaching 10 MSEK in ARR by year-end. Despite seasonal effects, the number of dispensings increased by 5% in June compared to May – a clear indication that Dosell usage continues to rise as more units are deployed and used consistently.

We carried out a directed share issue that brought approximately 10 MSEK into the company, strengthening our position to continue growing in Sweden and across our prioritized international markets.

We also launched an exclusive offer for our shareholders – for a limited time, shareholders can receive a Dosell with a free subscription. This is an opportunity to try the product firsthand, contribute to better medication management, and become an ambassador for tomorrow’s solution.
We’ve already received enthusiastic responses and interest in the offer, which is very encouraging. I truly hope even more shareholders take this chance to try Dosell and experience the value it delivers – both for individuals and for society.

Read more and register here: https://dosell.se/aktieagarforman/

Sweden: Summer Pause in Municipalities – But Strong Momentum in Dialogue and Planning
Swedish municipalities are entering a summer period where many processes slow down due to holidays and temporary staffing. This is reflected in a temporarily slower pace, but we’ve taken the opportunity to focus on preparations for the autumn.

In June, we conducted no fewer than 18 digital product demos for municipalities that have shown curiosity and interest. We’ve also been working intensively on fall planning for the launches and pilots scheduled to begin in September.

Feedback from existing customers remains strong – as one put it: “I hear nothing but that it works great!”

Spain: Ti Medi Expands – Strong Media Coverage and Expansion Planning
Our partner Ti Medi continues to expand through the national pharmacy network and has also gained significant media attention. A recently published article in La Vanguardia about their initiative has spread widely and generated additional interest.

The focus now is to continue scaling within Spain – but also to bring Dosell to new countries. Ti Medi is now preparing for launches in both Portugal and France this fall.

The Netherlands: 21% Growth in June – Over 30 Care Organizations in Operation
The Netherlands continues to deliver impressive results. In June alone, the number of active units with our partner grew by 21%, with an additional 21% growth expected in July based on the current pipeline.

Our partner drove more than 300 kilometers in a single week to meet with partners, deliver Dosell units, and identify specific needs in each organization. The Netherlands now has over 30 care organizations using Dosell – clear proof of both the demand and scalability of the solution.

Unlike Sweden, several Dutch organizations choose to launch during the summer. As one partner put it: “We have to start now – we simply don’t have the resources to help our users manage their medication without Dosell.”

At the same time, development of further integrations with other platforms is ongoing, making it easier for new organizations to implement Dosell. Several existing customers are also significantly scaling up their usage volumes.

Other Markets: Rising Interest Across New Regions
We continue to engage in dialogue with several new markets expressing interest in implementing Dosell. The need for safer and more efficient medication management is global – and we see strong potential in scaling our model to more countries.

Thank you for following our journey – and a special thanks to all shareholders engaging with Dosell. Together, we continue shaping the future of medication management.

iZafe Group introducerar nu ett nytt exklusivt förmånserbjudande för aktieägare. Alla som äger aktier i iZafe till ett värde av minst 50 000 kronor erbjuds en kostnadsfri Dosell med 100 % rabatt på abonnemanget.

Syftet med erbjudandet är att belöna lojalitet och samtidigt ge fler möjlighet att uppleva nyttan av Dosell – en läkemedelsautomat som bidrar till ökad trygghet och följsamhet i medicinering.

Erbjudandet tillhandahålls genom iZafes helägda dotterbolag Dosell AB.
 
Villkor i korthet:

  • Gäller för privatpersoner som äger aktier i iZafe Group AB (publ) för minst 50 000 kronor
  • Aktievärdet baseras på senast tillgängliga stängningskurs
  • Erbjudandet gäller en (1) Dosell med kostnadsfritt abonnemang
  • Gäller så länge aktieinnehavet uppgår till minst 50 000 kronor
  • Gäller endast för leveranser inom Sverige

För mer information och anmälan: https://dosell.se/aktieagarforman/

Vi ser detta som ett naturligt steg i vår ambition att både öka värdet för våra aktieägare och sprida användningen av Dosell i samhället.

iZafe Group AB (publ) ("iZafe" or the "Company") announces today that the Board of Directors has resolved, based on the authorization granted by the Annual General Meeting on May 28, 2025, on a directed share issue of 43,478,261 Class B shares at a subscription price of SEK 0.23 per share, with deviation from the shareholders' preferential rights (the "Directed Share Issue"), to external investors as well as a number of existing shareholders. The subscription price corresponds to a discount of approximately 11.5 percent compared to the closing price on Nasdaq First North Growth Market on June 26, 2025. Through the Directed Share Issue, iZafe will receive gross proceeds of approximately SEK 10 million before issue-related costs.

“Over the past six months, we have taken important steps that strengthen our market position – with clear growth in both Sweden and the Netherlands as well as strong demand from additional markets. At the same time, we are seeing a multiplied revenue and a steady increase in active units. By now raising new capital from both long-term shareholders and new investors, we ensure that we can continue to develop the business at a high pace and deliver according to the plan we have clearly communicated. This share issue is a sign of strength and a result of the trust that has been built – not only in our product portfolio, but also in the team, our strategy, and the market potential ahead. We are convinced that this step benefits all shareholders and lays the foundation for continued growth and value creation,” comments Anders Segerström, CEO of iZafe Group AB.

The Directed Share Issue
The Directed Share Issue comprises 43,478,261 Class B shares and has been resolved by the Board of Directors based on the authorization granted by the Annual General Meeting held on May 28, 2025. The right to subscribe for shares in the Directed Share Issue is granted to external investors and a number of existing shareholders. The subscription price is SEK 0.23 per share, representing a discount of approximately 11.5 percent compared to the closing price on Nasdaq First North Growth Market on June 26, 2025. The subscription price has been determined through arm’s length negotiations with external investors in the Directed Share Issue, in consultation with the Company’s financial advisor Stockholm Corporate Finance AB, and based on an analysis of several market factors. The Directed Share Issue also enables the Company to capitalize on the current interest in the Company’s shares among the subscribers at a price in line with the prevailing market price. The Board of Directors therefore assesses that the subscription price has been determined on market terms considering current market conditions. Through the Directed Share Issue, the Company will receive approximately SEK 10 million before transaction-related costs, which are estimated to amount to approximately SEK 0.29 million. The subscribers in the Directed Share Issue include both existing long-term shareholders of the Company – Eva Redhe, Gästrike Nord Invest AB, Stefan Wård, Filippa Landström, Junior Farma S.L. and Massimiliano Franzé – and new shareholders Erik Dahlberg, Rustan Panday, and Olle Olsson.

Background and Rationale for the Directed Share Issue
The purpose of the Directed Share Issue is to finance accelerating growth, execute strategic investments, and strengthen liquidity to enable repayment of an existing loan including interest, amounting to SEK 5.7 million, from Exelity AB. The remaining capital, approximately SEK 4.3 million before issue-related costs, strengthens iZafe’s working capital and ensures greater capacity to meet the clearly increasing demand for Dosell in existing and new markets.

Deviation from the Shareholders’ Preferential Rights
The purpose of the Directed Share Issue and the reason for the deviation from the shareholders’ preferential rights is to carry out a capital raise in a time- and cost-efficient manner. The Board has evaluated the possibility of primarily conducting a rights issue. The Company has weighed the advantages and disadvantages of a rights issue compared to a directed share issue and concluded that a rights issue (i) would be significantly more time-consuming and may risk the Company missing potential growth opportunities, (ii) would result in considerably higher issue-related costs, primarily due to the procurement of a guarantee consortium and legal fees, (iii) would expose the Company to greater market volatility, and (iv) would likely need to be conducted at a lower subscription price and result in higher dilution, which would disadvantage all shareholders. In addition, a rights issue would not provide the Company with capital in time to repay short-term debt financing, thus impairing the ability to meet such obligations. The Directed Share Issue also allows the Company to take advantage of current investor interest in its shares at a price aligned with the prevailing market price. Given the above and after careful consideration, the Board assesses that the Directed Share Issue is the most favorable financing option for iZafe and in the best interest of both the Company and its shareholders, and therefore also justifies a deviation from the main rule of shareholders’ preferential rights. The subscription price in the Directed Share Issue has been determined through arm’s length negotiations with the new external investors, based on the prevailing share price of the Company’s Class B shares. Furthermore, the Board has ensured the market-based nature of the subscription price in consultation with financial advisors, based on current market conditions and previously indicated price levels in discussions with potential investors. In the Board’s assessment, the market terms of the price have thus been confirmed through this process. The reason for including existing shareholders in the Directed Share Issue is partly that this was part of the negotiation with the new external investors, and partly because the Board deemed it strategically wise to include these long-term and committed shareholders in the Directed Share Issue – to help strengthen the credibility and trust in the Company on the market, for the benefit of all shareholders.

Number of Shares, Share Capital, and Dilution
Through the Directed Share Issue, the Company’s share capital will increase by SEK 2,173,913.05, from SEK 16,086,808.55 to SEK 18,260,721.60, through the issuance of 43,478,261 Class B shares. This means that the total number of shares will increase from 321,736,171 to 365,214,432 shares, of which 600,000 are Class A shares carrying ten (10) votes per share at the general meeting, and 364,614,432 are Class B shares carrying one (1) vote per share. The Directed Share Issue entails a dilution of approximately 11.9 percent of the share capital for existing shareholders, calculated as the number of Class B shares issued in the Directed Share Issue divided by the total number of shares in the Company after the share issue.

Advisors
Stockholm Corporate Finance is acting as financial advisor and LW Advisory as legal advisor to iZafe in connection with the Directed Share Issue. Aqurat Fondkommission is acting as issuing agent in connection with the Directed Share Issue.

Important Information
The publication, release, or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions and persons in jurisdictions where this press release has been published or distributed must inform themselves of and comply with such legal restrictions. Recipients of this press release are responsible for using it and the information contained herein in accordance with applicable rules in their respective jurisdictions. This press release does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities issued by the Company in any jurisdiction where such offer or solicitation would be unlawful or would require additional registration or other measures.

This press release does not constitute an offer to buy or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States without registration under, or an exemption from, the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced, or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, Russia, Belarus, or any other jurisdiction where such announcement, publication, or distribution would be contrary to applicable regulations or would require additional registration or other measures than those required under Swedish law. Any failure to comply with this instruction may constitute a violation of the Securities Act or applicable securities laws in other jurisdictions.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. The Company has not approved any offer to the public of securities in any EEA member state and no prospectus has been or will be prepared in connection with the Directed Share Issue. In each EEA member state, this communication is only addressed to “qualified investors” in that member state as defined in the Prospectus Regulation.

This press release does not identify or purport to identify the risks (direct or indirect) that may be associated with an investment in the new shares. Any investment decision to acquire or subscribe for new shares in the Directed Share Issue must be made solely based on publicly available information, which has not been independently verified by the financial advisor.

This press release does not constitute a recommendation concerning any investor’s decision regarding the Directed Share Issue. Each investor or potential investor should conduct their own investigation, analysis, and evaluation of the business and information described in this press release and all publicly available information. The price and value of securities can decrease as well as increase. Past performance is not an indication of future performance. Neither the content of the Company’s website nor any other website accessible through hyperlinks on the Company’s website is incorporated into or forms part of this press release.

Failure to comply with these instructions may constitute a violation of the Securities Act or applicable laws in other jurisdictions.

Forward-looking Statements
This press release contains forward-looking statements that reflect the Company’s intentions, beliefs, or current expectations regarding and targets for the Company’s future operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies, and opportunities, as well as the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified by words such as “believe,” “expect,” “anticipate,” “intend,” “may,” “plan,” “estimate,” “will,” “should,” “could,” “aim” or “might,” or, in each case, their negative or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which in turn are based on additional assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes could differ materially from those described in the forward-looking statements. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations expressed or implied by the forward-looking statements in this press release. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are error-free and accepts no responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. The information, opinions, and forward-looking statements contained in this press release speak only as of its date and may be subject to change without notice. The Company undertakes no obligation to review, update, confirm, or release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release.

May has been an eventful month where we took yet another important step forward. The number of active billable Dosell units increased by an additional 14% from April – a growth now built on an ever-larger base volume. At the same time, we passed a major symbolic milestone: more than 1,000 active units in operation, showing that we’ve made it through the most challenging phase – building a stable, scalable, and in-demand solution.

Growth is driven both by more municipalities and partners starting to use Dosell – and by existing customers prescribing more units per client. We are seeing broad and growing traction, even though we’re still coming from relatively modest volumes. That makes the strength of our growth rate all the more encouraging.

We are now entering the summer months, which traditionally means a somewhat slower pace due to holidays. But we look forward to ramping up again in the fall – firmly anchored in our long-term strategy.

Sweden: Growth in VGR and Increasing Demand Ahead of Autumn
In May, two more municipalities in the Västra Götaland region (VGR) began using Dosell, bringing our presence in the region to 14 municipalities. Several of these have started increasing their internal volumes and are receiving very positive feedback from both staff and users.

Two new municipalities have approved pilot projects with Dosell set to start right after summer. We’ve also held numerous presentations for municipalities now considering launching their own pilots – a clear sign of the strong momentum we’re experiencing in the Swedish public care sector.

At Vitalis, the Nordic region’s leading event for health and social care, we gained strategic traction – both through our presence and by presenting collaborations with Tamro, JDM Innovation, and Phoenix Group. The reaction from visitors was overwhelmingly positive, summarized best by the comment: “Finally, two solutions in one system!”

Especially appreciated was our joint stage appearance with ATEA and Ulricehamn Municipality, where Ulricehamn shared their successful implementation and how their “slow and steady” approach has led to stable, positive development. Many home care teams in the municipality are now reaching out, eager to start using Dosell themselves.

We also participated in Senior Day in Kungsträdgården, where we received great interest in our consumer solution. At the same time, our partner Zafe exhibited at the Dementia Days event, where Dosell attracted significant attention for its value in early intervention for cognitive impairment. The new Social Services Act emphasizes this very need – and many now see Dosell as a key part of the solution.

Spain: Pharmacy Network and Interest from Private Care Providers
In Spain, our partner Ti Medi continues rolling out Dosell through the national pharmacy network, which includes over 1,500 pharmacies.

Following strong media attention in April, private care providers have also started to show interest in Dosell. Our B2B solution is now being actively presented to these providers, who see the opportunity to complement their existing care structures with a digital solution that enhances independence and safety in medication management.

The Netherlands: Continued Growth and Trade Fair Momentum
In the Netherlands, growth continues at a rapid pace. Our customer TCCN is highly engaged and has established an efficient approach for broad outreach – already leading to concrete meetings with new stakeholders. At the same time, their existing customers are increasing their volumes month over month.

Dosell TV has generated strong interest, and our presence at the April trade fair served as a clear catalyst for new contacts. Several of these are now in the quotation or implementation phase. The combination of proactive sales, a strong network, and a value-driven offering that meets real needs gives us excellent conditions for continued expansion together with TCCN.

Strategic Partnership – LOI with JDM Innovation
In May, we signed a Letter of Intent with JDM Innovation, aiming to establish a strategic partnership in Europe. JDM is a well-established player in logistics, automation, and medical technology, working with both international pharmaceutical companies and pharmacy chains.

The partnership creates opportunities to integrate our technologies and opens doors to new markets in Europe. Discussions around joint pilots are already underway, and we see great potential in driving efficiency and safe medication management together in new markets.

Celebrate the 1,000-Unit Milestone with Us – Investor Evening June 12
To mark our achievement of surpassing 1,000 active units, we’re inviting you to an investor evening in Stockholm – on Thursday, June 12.

We sincerely hope as many shareholders as possible will take this opportunity to come, meet our team in person, ask questions, and get deeper insight into our journey and future vision. It’s a great chance to connect – and to experience Dosell live.

Welcome – we look forward to seeing you! Register here: https://forms.office.com/e/8qHzwLu5S8

Thank You for Your Trust – Together We Are Shaping the Future of Medication Management
iZafe Group is in a phase of strong commercial momentum. May’s results confirm both the direction and pace of our progress. We’re strengthening our partnerships, expanding our network, and building on a model that has now proven both scalable and effective.

Thank you for following our journey – and we warmly welcome you to the investor evening on Thursday, June 12.

iZafe Group AB (publ) (“iZafe” or “the Company”) today announces that its subsidiary Dosell has reached a significant milestone: more than 1,000 active Dosell units are now in use across Europe. This marks a clear breakthrough for safe and digital medication management in the home.

To celebrate this achievement, the company invites shareholders, partners, healthcare professionals and other stakeholders to an exclusive event at its Stockholm office on June 12.

“This milestone is both personal and strategic. Reaching 1,000 Dosell units in operation proves that we’ve made it through the most challenging phase – building a stable, scalable and in-demand solution. Now we’re ready to grow in earnest. None of this would have been possible without the tremendous dedication of our team, our partners, and our shareholders who believed in us every step of the way. I look forward to sharing the next chapter with you,” says Anders Segerström, CEO of iZafe Group.

During the evening, we will share the journey toward reaching 1,000 active Dosell units – the challenges we’ve faced, the key turning points, and why this moment represents a breakthrough for both our company and the digital healthcare sector.

You’ll also get a glimpse of what’s coming next – our strategic goals, technical roadmap, and how we plan to scale up the business both in Sweden and internationally.

Food and drinks will be served in a relaxed setting where you’ll have the opportunity to connect with the Dosell team, fellow shareholders, healthcare innovators, and industry professionals.

Event Details:

Please note that registration is required and space is limited – spots will be allocated on a first-come, first-served basis.

About Dosell
Dosell is a medical technology solution that ensures the right person takes the right medication at the right time. The product is specifically designed to prevent double dosing and improve adherence – one of the greatest challenges in modern healthcare. Dosell is currently used by municipalities, private care providers and partners across Europe.

Årsstämman i iZafe Group AB, orgnr. 556762-3391, (”Bolaget”) ägde rum torsdagen den 28 maj 2025 på Bolagets kontor. Årsstämman beslutade, bland annat följande:

Fastställande av resultat- och balansräkning
Fastställande av resultat- och balansräkning för moderbolaget och koncernen för räkenskapsåret 2024.

Utdelning
Stämman beslutade att ingen utdelning lämnas och att årets resultat balanseras i ny räkning.

Styrelse och revisor
Stämman beviljade styrelseledamöterna och verkställande direktören ansvarsfrihet för räkenskapsåret 2024.

Stämman beslutade att styrelsen ska bestå av fyra ordinarie ledamöter utan suppleanter. Stämman beslutade om omval av Richard Wolff till styrelseordförande samt om omval av Jenny Styren till ordinarie styrelseledamot. Stämman beslutade om nyval av Anna Håkansson och Samuel Danofsky till styrelseledamöter. Den auktoriserade revisorn Johan Kaijser omvaldes till Bolagets revisor för tiden intill slutet av nästa årsstämma.

Styrelse- och revisorsarvode
Stämman fastställde styrelsearvode med 117 600 kronor och arvode till styrelseordförande med 176 400 kronor. Alla ersättningar som en styrelseledamot erhåller från Bolaget i enhetlig med godkända uppdragsavtal kan avräknas mot styrelsearvodet. Arvode till revisorn ska utgå enligt godkänd räkning.

Bemyndigande för styrelsen att fatta beslut om emission av aktier, teckningsoptioner och konvertibler
Stämman fastställde att bemyndiga styrelsen att – vid ett eller flera tillfällen och längst intill nästkommande årsstämma – besluta om att öka Bolagets aktiekapital genom nyemission av aktier samt att emittera teckningsoptioner och konvertibler motsvarande högst tjugo (20) procent av det totala antalet utestående aktier i Bolaget vid den tidpunkt då styrelsen första gången utnyttjar bemyndigandet. Nyemission av aktier eller emission av teckningsoptioner eller konvertibler ska ske till marknadsmässiga villkor och ska kunna ske med eller utan företrädesrätt för aktieägarna samt med eller utan bestämmelse om apport, kvittning eller andra villkor.

Ändring av bolagsordningen samt minskning av aktiekapitalet för avsättning till fritt eget kapital
Stämman beslutade om ändring av bolagsordningens gränser för aktiekapitalet från lägst 50 000 000 kronor och högst 200 000 000 kronor till lägst 15 000 000 kronor och högst 60 000 000 kronor, samt om minskning av aktiekapitalet med 46 527 925,65 kronor för avsättning till fritt eget kapital. Minskningen av aktiekapitalet sker utan indragning av aktier. Efter minskningen av aktiekapitalet kommer Bolagets aktiekapital att uppgå till 15 509 308,55 kronor, fördelat på sammanlagt 310 186 171 aktier, varav 600 000 A-aktier som ger rätt till tio (10) röster per aktie på bolagsstämma och 309 586 171 B-aktier som ger rätt till en (1) röst per aktie på bolagsstämma. Samtliga aktier kommer efter minskningen att ha ett kvotvärde om 0,05 kronor per aktie. Beslutet om minskning av aktiekapitalet kräver tillstånd från Bolagsverket eller allmän domstol.

Webbdesign av Comlog Webbyrå Stockholm